Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS2R14 | Q9NYV8 | 3/20 | 0.67 |
| ▸ | DHODH | Q02127 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | FABP4 | P15090 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15352107 | 0.98 | TAS2R14 (0.65) | TAS2R14DHODHHDAC6CTSSFABP4 | |
| SCHEMBL28052031 | 0.86 | TAS2R14 (0.55) | TAS2R14DHODHHDAC6CTSSLMNA | |
| SCHEMBL29656425 | 0.85 | TAS2R14 (0.54) | TAS2R14DHODHHDAC6CTSSLMNA | |
| SCHEMBL12327907 | 0.85 | TAS2R14 (0.54) | TAS2R14DHODHHDAC6CTSSLMNA | |
| SCHEMBL1966015 | 0.84 | TAS2R14 (0.58) | TAS2R14DHODHHDAC6FABP4LMNA | |
| SCHEMBL29629424 | 0.83 | TAS2R14 (0.53) | TAS2R14DHODHHDAC6CTSSTSHR | |
| SCHEMBL2576656 | 0.83 | TAS2R14 (0.53) | TAS2R14DHODHHDAC6CTSSTSHR | |
| SCHEMBL5370256 | 0.83 | TAS2R14 (0.53) | TAS2R14DHODHHDAC6CTSSLMNA | |
| SCHEMBL10397067 | 0.82 | TSHR (0.49) | TAS2R14DHODHHDAC6TSHRLMNA | |
| SCHEMBL10053348 | 0.82 | TAS2R14 (0.51) | TAS2R14DHODHHDAC6ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3088487-B1 | SURFACE TREATING AGENT INCLUDING PERFLUORO(POLY)ETHER-GROUP-CONTAINING SILANE COMPOUND | DAIKIN IND LTD (JP) | 2021-05-05 | — | — | EP | claimed |
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| US-20060128984-A1 | Method of preparing an ester of an aromatic carboxylic acid bearing at least one perfluoroalkyl group | CHIMIE, RHODIA (FR) | 2006-06-15 | — | — | US | claimed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| EP-4655296-A1 | CBL-B INHIBITORS | Aurigene Oncology Limited (IN) | 2025-12-03 | — | — | EP | disclosed |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | GENENTECH, INC. (US) | 2025-07-17 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| EP-4562016-A2 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | Cedilla Therapeutics, Inc. (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4267574-B1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12247027-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2025-03-11 | — | — | US | disclosed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | PHARMACIA CORPORATION | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
| JP-2004002337-A | METHOD FOR PRODUCING METHYLTRIFLUOROMETHYLBENZOIC ACID | CENTRAL GLASS CO LTD | 2004-01-08 | — | — | JP | disclosed |
| US-6617324-B1 | Phenyl, cyclohexyl and pyridinyl or pyrimidinyl-substituted | G. D. SEARLE & COMPANY | 2003-09-09 | — | — | US | disclosed |
| US-6525059-B1 | Mitogen-activated protein kinases (MAP); | G. D. SEARLE & COMPANY | 2003-02-25 | — | — | US | disclosed |
| US-6514977-B1 | For treating p38 kinase mediated disorders | G.D. SEARLE & COMPANY | 2003-02-04 | — | — | US | disclosed |
| US-6423713-B1 | Substituted pyrazoles as p38 kinase inhibitors | G. D. SEARLE & COMPANY | 2002-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | TAS2R14 4738/4885DHODH 1894/4885HDAC6 444/4885 |
| US-12247027-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | TAS2R14 2225/4885DHODH 3071/4885HDAC6 2726/4885 |
| US-20250230147-A1 | LACTAMS AS CBL-B INHIBITORS | CBLB, CBL, CBLC | TAS2R14 4317/4885DHODH 2481/4885HDAC6 3024/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | TAS2R14 4229/4885DHODH 2951/4885HDAC6 2635/4885 |
| US-20040176433-A1 | treatment of tumor necrosis factor mediated disorders; asthma; inflammatory bowel disease; arthritis | MAPK1, IL1R1, TNF | TAS2R14 2867/4885DHODH 2034/4885HDAC6 2347/4885 |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | TAS2R14 3992/4885DHODH 60/4885HDAC6 55/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | TAS2R14 4229/4885DHODH 2951/4885HDAC6 2635/4885 |
| US-20060128984-A1 | Method of preparing an ester of an aromatic carboxylic acid bearing at least one perfluoroalkyl group | ALK, PAH, PFAS | TAS2R14 1989/4885DHODH 1032/4885HDAC6 4079/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.